No cooling off for pharma digital transformation in 2021COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life Share XNo cooling off for pharma digital transformation in 2021https://pharmaphorum.com/views-analysis-digital/no-cooling-off-for-pharma-digital-transformation-in-2021/
UK patient group warns COVID could limit access to Novartis’ new eye drugNICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – Share XUK patient group warns COVID could limit access to Novartis’ new eye drughttps://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/
FDA approves Bayer/Merck & Co heart failure drugBayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand Share XFDA approves Bayer/Merck & Co heart failure drughttps://pharmaphorum.com/news/competition-mounts-in-heart-failure-fda-approves-bayer-merck-co-drug/
Bayer joins the COVID-19 vaccine push, backing CureVac shotShortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to Share XBayer joins the COVID-19 vaccine push, backing CureVac shothttps://pharmaphorum.com/news/bayer-joins-the-covid-19-vaccine-push-backing-curevacs-shot/
Bayer provides funding to five more digital health start-upsBayer has provided funding to five more digital health start-ups as part of its G4A partnering programme, which Share XBayer provides funding to five more digital health start-upshttps://pharmaphorum.com/news/bayer-provides-funding-to-five-more-digital-health-start-ups/
Europe approves Roche’s Tecentriq liver cancer combinationThe European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients Share XEurope approves Roche’s Tecentriq liver cancer combinationhttps://pharmaphorum.com/news/europe-approves-roches-tecentriq-liver-cancer-combination/
Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
Bayer data for kidney disease hope finerenone sets up filingsBayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication Share XBayer data for kidney disease hope finerenone sets up filingshttps://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
